The primary object of this trial is to evaluate the 2-year local control rate adding extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma.

Inclusion Criteria:

• Joined the study voluntarily and signed informed consent form;
• Age 18-75；ECOG 0-2
• Esophageal squamous cell carcinoma , radical surgery ≤3 months,R0 resection. The operative incision healed well.
• T3-4N0M0, T1-4N1-3M0 (according to AJCC2009)
• No radiotherapy, chemotherapy or other treatments pre(post)surgery
• PS ECOG 0-2
• Life expectancy of more than 3 months
• Hemoglobin(Hb)≥9 g/dL • WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L • platelet count (Pt) ≥100x 109/L • Hepatic function: ALAT and ASAT < 2.5 x ULN, TBIL<1.5 x ULN • Renal function: creatinine < 1.5 x ULN
• No immuno-deficiency
• Use of an effective contraceptive for adults to prevent pregnancy.

Exclusion Criteria:

• Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis
• Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years
• Participation in other interventional clinical trials within 30 days
• Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives
• Drug addiction, Alcoholism or AIDS
• Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior
• Unsuitable to be enrolled in the trial in the opinion of the investigators